The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
The company is scaling up manufacturing and commercial activities as it prepares to enter the U.S. market via the Food and Drug Administration’s de novo pathway.
StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Repligen (NASDAQ:RGEN) vs the rest of the pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Charles River Laboratories (NYSE:CRL) vs the rest of the pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
SCOTUSblog on MSN
Uninjured class members, hindsight harmlessness, presidential cronies, and the mistaken use of deadly force
The Relist Watch column examines cert petitions that the Supreme Court has “relisted” for its upcoming conference. A short explanation of relists is available here. There are 261 petitions and ...
Detailed price information for Medpace Holdings Inc (MEDP-Q) from The Globe and Mail including charting and trades.
IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 March 10, 2026 2:00 PM EDTCompany ParticipantsMichael Feldschuh ...
Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and ...
Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth ...
Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results